Status:
UNKNOWN
Epigenetic Biomarker for Osteosarcoma
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Peking University
Northwestern University
Conditions:
Histologic Response (Tumor Necrosis Rate)
Objective Response Rate for Neoadjuvant Chemotherapy, ORR
Eligibility:
All Genders
10+ years
Brief Summary
hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-mod...
Detailed Description
The investigator want to enroll 100 osteosarcoma participants initially treated in Musculoskeletal Tumor Center of Peking University People's Hospital(PKUPH). All those participants will follow the ch...
Eligibility Criteria
Inclusion
- 1\) histologically confirmed high-grade osteosarcoma;
- 2\) older than 10 yrs;
- 3\) initially treated in Musculoskeletal Tumor Center of Peking University People's Hospital;
- 4\) Serum samples are available;
- 5\) completed neo-adjuvant chemotherapy and at least 8 cycles of adjuvant chemotherapy;
- 6\) expected to live longer than 3 months with Eastern Cooperative Oncology Group performance status of 0 or 1;
- 7\) acceptable hematologic, hepatic, and renal function.
Exclusion
- 1\) Serum samples are not qualified;
- 2\) Patients who could not complete neo-adjuvant chemotherapy or at least 4-month adjuvant chemotherapy;
- 3\) lost to follow-up.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03336554
Start Date
September 1 2017
End Date
December 31 2018
Last Update
November 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China, 100044